FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588548100> ?p ?o ?g. }

• W2588548100 endingPage "vi138" @default.
• W2588548100 startingPage "vi138" @default.
• W2588548100 abstract "Telotristat etiprate (TE) is an oral tryptophan hydroxylase inhibitor in development for the treatment of carcinoid syndrome (CS). During the placebo-controlled, 12-week double-blind treatment (DBT) periods of 2 Phase 3 studies, TELESTAR and TELECAST, TE significantly reduced bowel movement (BM) frequency compared to placebo. Objective: To examine the safety of TE vs placebo, a combined analysis of safety data from the DBT periods of TELESTAR and TELECAST was performed. 211 patients (pts) with CS were randomly assigned (1:1:1) to placebo or TE 250 mg or 500 mg, each given 3x/day (tid). At entry, pts on stable-dose long-acting somatostatin analog (SSA) therapy had ≥4 (TELESTAR) or <4 (TELECAST) BMs/day, while pts not on SSAs had ≥4 BMs/day (TELECAST). Antidiarrheals and short-acting rescue SSAs were allowed. Treatment-emergent adverse event (TEAE), serious adverse event (SAE), and adverse event of special interest (AESI) data were pooled. AESIs related to depression, hepatic enzyme elevation, and gastrointestinal (GI) symptoms were identified by prespecified preferred terms. 71 pts on placebo and 70 pts each on TE 250 mg or 500 mg tid were analyzed. At entry, 47% of pts were female, all pts had metastatic neuroendocrine tumors with mean disease duration of 7 yrs, mean BM frequency was 5.7 (TELESTAR) and 2.5 (TELECAST) BMs/day, and mean urinary 5-hydroxyindoleacetic acid was 84 mg/day. DBT period completion rates were similar between TE (88%) and placebo (87%) pts, as were incidences of SAEs and treatment withdrawal due to TEAE. Hepatic enzyme elevations were no greater than Drug-Induced Liver Injury Network Grade 1 (mild; on a scale up to 5). Slightly higher rates of nausea, constipation, and depression were reported with TE. There were no serious AESIs related to depression. Integrated safety analyses of placebo-controlled data support the proposed use of TE for the treatment of CS in patients receiving SSA therapy.Tabled 1TE# of pts with:Placebo n = 71250 mg tid n = 70500 mg tid n = 70≥1 TEAE606263≥1 SAE12810Death311Drug withdrawal due to TEAE12159AESIs- Depression related558- Hepatic enzymes0108- Any GI303232- Nausea9916- Vomiting536- Constipation245 Open table in a new tab" @default.
• W2588548100 created "2017-02-24" @default.
• W2588548100 creator A5005448318 @default.
• W2588548100 creator A5017947396 @default.
• W2588548100 creator A5018501366 @default.
• W2588548100 creator A5026573275 @default.
• W2588548100 creator A5028088650 @default.
• W2588548100 creator A5033095043 @default.
• W2588548100 creator A5033960518 @default.
• W2588548100 creator A5038614419 @default.
• W2588548100 creator A5040645190 @default.
• W2588548100 creator A5050005771 @default.
• W2588548100 creator A5053175288 @default.
• W2588548100 creator A5055143638 @default.
• W2588548100 creator A5057078499 @default.
• W2588548100 creator A5075068326 @default.
• W2588548100 creator A5077826150 @default.
• W2588548100 creator A5081606866 @default.
• W2588548100 creator A5081758034 @default.
• W2588548100 creator A5083493576 @default.
• W2588548100 date "2016-10-01" @default.
• W2588548100 modified "2023-10-01" @default.
• W2588548100 title "Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome" @default.
• W2588548100 doi "https://doi.org/10.1093/annonc/mdw369.07" @default.
• W2588548100 hasPublicationYear "2016" @default.
• W2588548100 type Work @default.
• W2588548100 sameAs 2588548100 @default.
• W2588548100 citedByCount "3" @default.
• W2588548100 countsByYear W25885481002017 @default.
• W2588548100 crossrefType "journal-article" @default.
• W2588548100 hasAuthorship W2588548100A5005448318 @default.
• W2588548100 hasAuthorship W2588548100A5017947396 @default.
• W2588548100 hasAuthorship W2588548100A5018501366 @default.
• W2588548100 hasAuthorship W2588548100A5026573275 @default.
• W2588548100 hasAuthorship W2588548100A5028088650 @default.
• W2588548100 hasAuthorship W2588548100A5033095043 @default.
• W2588548100 hasAuthorship W2588548100A5033960518 @default.
• W2588548100 hasAuthorship W2588548100A5038614419 @default.
• W2588548100 hasAuthorship W2588548100A5040645190 @default.
• W2588548100 hasAuthorship W2588548100A5050005771 @default.
• W2588548100 hasAuthorship W2588548100A5053175288 @default.
• W2588548100 hasAuthorship W2588548100A5055143638 @default.
• W2588548100 hasAuthorship W2588548100A5057078499 @default.
• W2588548100 hasAuthorship W2588548100A5075068326 @default.
• W2588548100 hasAuthorship W2588548100A5077826150 @default.
• W2588548100 hasAuthorship W2588548100A5081606866 @default.
• W2588548100 hasAuthorship W2588548100A5081758034 @default.
• W2588548100 hasAuthorship W2588548100A5083493576 @default.
• W2588548100 hasBestOaLocation W25885481001 @default.
• W2588548100 hasConcept C126322002 @default.
• W2588548100 hasConcept C142724271 @default.
• W2588548100 hasConcept C197934379 @default.
• W2588548100 hasConcept C204787440 @default.
• W2588548100 hasConcept C27081682 @default.
• W2588548100 hasConcept C71924100 @default.
• W2588548100 hasConcept C90924648 @default.
• W2588548100 hasConceptScore W2588548100C126322002 @default.
• W2588548100 hasConceptScore W2588548100C142724271 @default.
• W2588548100 hasConceptScore W2588548100C197934379 @default.
• W2588548100 hasConceptScore W2588548100C204787440 @default.
• W2588548100 hasConceptScore W2588548100C27081682 @default.
• W2588548100 hasConceptScore W2588548100C71924100 @default.
• W2588548100 hasConceptScore W2588548100C90924648 @default.
• W2588548100 hasLocation W25885481001 @default.
• W2588548100 hasOpenAccess W2588548100 @default.
• W2588548100 hasPrimaryLocation W25885481001 @default.
• W2588548100 hasRelatedWork W1977915442 @default.
• W2588548100 hasRelatedWork W2085830368 @default.
• W2588548100 hasRelatedWork W2109282245 @default.
• W2588548100 hasRelatedWork W2163740414 @default.
• W2588548100 hasRelatedWork W2374781999 @default.
• W2588548100 hasRelatedWork W2976934717 @default.
• W2588548100 hasRelatedWork W2987544514 @default.
• W2588548100 hasRelatedWork W4233016836 @default.
• W2588548100 hasRelatedWork W4312071120 @default.
• W2588548100 hasRelatedWork W59643826 @default.
• W2588548100 hasVolume "27" @default.
• W2588548100 isParatext "false" @default.
• W2588548100 isRetracted "false" @default.
• W2588548100 magId "2588548100" @default.
• W2588548100 workType "article" @default.